Grifols Gains FDA Approval for VISTASEAL Fibrin Sealant in Surgical Hemostasis Indication

A multi-supplement BLA lifecycle spanning nearly a decade positions Instituto Grifols, S.A. as a reference case for biologics post-approval strategy, with the December 6, 2024 approval letter for VISTASEAL marking the most recent regulatory action under BL 125640. For regulatory affairs leads managing complex biologics portfolios, the approval history documents a structured cadence of supplements and reviews that reflects current expectations under ICH Q10 for lifecycle management.

VISTASEAL (Fibrin Sealant, Human) is indicated as an adjunct to hemostasis for mild to moderate bleeding in adults undergoing surgery where standard techniques, suture, ligature, and cautery, are ineffective or impractical. The product is also indicated for use in heparinized patients, a clinically relevant extension that broadens its intraoperative utility. The original BLA approval was granted November 1, 2017, with subsequent approval letters issued June 21, 2022, and September 27, 2024, before the December 2024 action.

The supporting document set released alongside the December approval includes a Clinical Review Memo and Statistical Review Memo, both dated September 27, 2024, alongside the corresponding approval letter from the same date. Regulatory teams should note the parallel dating of the clinical and statistical memos against an earlier approval letter, a sequencing pattern that warrants close reading when mapping review timelines for analogous BLA supplements. The November 2017 Summary Basis for Regulatory Action remains the foundational reference for the product's clinical and manufacturing baseline.

For QA directors and plant heads at biologics manufacturers, the VISTASEAL file illustrates how a human plasma-derived product navigates iterative post-approval supplements while maintaining GMP compliance across a manufacturing site subject to 21 CFR Part 211 and biologics-specific requirements under 21 CFR Part 600. Instituto Grifols, S.A. as the named manufacturer carries the site-level accountability for each supplement cycle, a structural point relevant to any organization managing multi-site or multi-supplement biologics BLAs.

Demographic subgroup data, referenced in Section 1.1 of the Clinical Review Memo, is available for review, a detail that regulatory affairs professionals preparing labeling or post-market commitments for comparable products should factor into their own clinical review strategies.

The December 2024 approval letter and its associated review documents are publicly accessible via the FDA biologics approval database, providing a traceable record against which teams can benchmark their own BLA supplement timelines and documentation standards.

Source: FDA Center for Biologics Evaluation and Research (CBER) via FDA.gov Vaccines, Blood and Biologics RSS Feed, June 8, 2026.